-
Sector Analysis
Gastroparesis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
The gastroparesis pipeline consists of 17 pharmaceuticals spanning all stages of development, with approximately 90% of the drugs in early-stage development. Antagonists targeting the D2 receptor are expected to remain an important mechanism of action within the gastroparesis space. The report provides a data-driven overview of the current and future competitive landscape in gastroparesis therapeutics. Gastroparesis is a chronic disease characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach. Patients with gastroparesis...
-
Sector Analysis
Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. Seizures result from abnormal electrical discharges in the brain and vary in their manifestations, from the brief staring spells that are characteristic of absence seizures, to full-body convulsions known as tonic-clonic seizures. Seizures in children are among the most common neurological disorders. The childhood epilepsy market report includes an assessment of the pipeline and the clinical and commercial landscapes of childhood epilepsy, along with an analysis of key...
-
Sector Analysis
Fragile X Syndrome – Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2030
The Fragile X syndrome (FXS) market size in the 2MM was valued at $21.9 million in 2020. The market is projected to grow at a CAGR of over 7% during the forecast period. Since there are currently no approved therapies available, prescribed treatments are exclusively off-label drugs that target individual symptoms of the disease. Despite behavioral and educational interventions, patients with FXS continue to present with significant impairments in their functioning throughout life. It is suggested that an FXS-specific treatment...
-
Sector Analysis
Eosinophilic Esophagitis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Stratergies and Forecast, 2020 – 2030
The eosinophilic esophagitis (EoE) market in the US was valued at $156.7 million in 2020. The market is projected to grow at a CAGR of more than 25% during the forecast period. The COVID-19 pandemic did not impact the EoE market in 2020. Although the uptake of high-priced biologics is expected to be slow, they are expected to capture significant growth revenue over the next 10 years. A large number of symptomatic treatments are currently used off-label. The most frequently...
-
Sector Analysis
Duchenne Muscular Dystrophy – Opportunity Assessment and Forecast to 2030
The duchenne muscular dystrophy (DMD) market across the US and Japan was valued at $619.0 million in 2020. The market is projected to grow at a CAGR of more than 11% during the forecast period 2021-2030. The diagnosed prevalent cases of DMD are expected to increase in the US and decrease in Japan between 2020 to 2030. In 2020, the most prevalent mutation among DMD cases across both markets was deletion mutation. The least prevalent mutation type in both markets...
-
Company Insights
Future Unicorns in Healthtech
Based on the GlobalData Machine Learning Model’s proprietary ranking of 10,000 top startups, 120 Healthtech startups have been shortlisted globally, with 50 of them predicted to become future unicorns. The 10k top startups in the Scorecard are spread over 70 countries with the US accounting for half of them, followed by China. Positive sentiments in the news, continued VC investments, increase in hiring clubbed with growing Healthtech mentions in Company Filings indicate that the Healthtech sector has high interest for...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines-Global Market Forecast to 2024
This publication is an update and extension to the Excel model containing the patient-based sales forecast for COVID-19 vaccines, which was previously covered in Coronavirus Disease 2019 (COVID 19) Vaccines: Opportunity Assessment and Forecast to 2026, published in June 2021. Report deliverables include a PowerPoint report and an interactive Excel-based forecast model Forecasts includes 7MM (US, France, Germany, Italy, Spain, UK, and Japan) Forecasts cover 5 years from 2021 to 2026 GlobalData forecast three different potential scenarios for the future...
-
Company Insights
Future Unicorns in Fintech
Based on the GlobalData Machine Learning Model’s proprietary ranking of 10,000 top startups, 120 fintech startups have been shortlisted globally with 50 of them predicted to become future unicorns. The 10k top startups in the scorecard have spread over 70 countries with the US accounting for half of them, followed by China. Positive sentiments in news, continued VC investments, increase in hiring clubbed with growing fintech mentions in company filings indicate that the fintech sector has high interest for both...
-
Sector Analysis
Axillary Hyperhidrosis Market Size, Share & Trends Analysis and Forecast 2020-2030
The axillary hyperhidrosis (AH) market in the US has been valued at $65.6 million in 2020 and is projected to grow at a CAGR of more than 15% during the period 2021-2025. The sales of high-priced neuromuscular blockades represent the most impactful driver of growth for the AH market, but limited disease awareness will remain the main barrier and will keep diagnosis and treatment of cases at a low rate. The impacts of the COVID-19 pandemic have limited the size...
-
Thematic Analysis
Future Unicorn Predictions – Spot Tomorrow’s Winners Today
This report compendium consists of 5 reports that are based on GlobalData’s proprietary ranking of 10,000 top startups. The list has been compiled using GlobalData’s Quant-based Startup Scorecard tool combined with proprietary Machine Learning (ML) algorithms. The tool accurately predicts promising future Unicorns (Startups predicted to be valued at US$1bn or more) by analyzing the crucial indicators of previously identified Unicorns. Use GlobalData’s intelligence to help you to spot tomorrow’s winners today.